RALEIGH, N.C., July 22, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that its Board of Directors has appointed Charles J. (Chuck) Bramlage and Dr. Barry I. Feinberg as members of the Board.
Mr. Bramlage is a veteran pharmaceutical industry executive with extensive experience in marketing, sales and other commercial functions. He is currently the Chief Executive Officer of Pearl Therapeutics, Inc., a development stage company that was recently acquired by AstraZeneca and is focused on treatments for respiratory diseases. He previously served as President of Pharmaceutical Products at Covidien plc and President of European Operations at Valeant Pharmaceuticals International, Inc. For eighteen years, Mr. Bramlage held positions of increasing responsibility at GlaxoSmithKline plc, ultimately becoming Vice-President of Respiratory Global Commercial Development and Vice-President of U.S. Respiratory and Cardiovascular Marketing, where he led the team responsible for the global launch of Seretide®/Advair® and the U.S. launch of Flovent®.
Dr. Feinberg is a noted specialist in the area of pain management where he is board certified. Since 2008, he has served as a member of the Board of Directors and Medical Executive Committee of the Frontenac Surgery and Spine Care Center in St. Louis, Missouri, where he maintains his private practice under the name Injury Specialists. He has served as a staff member of the Department of Anesthesia at the Missouri Baptist Medical Center in St. Louis, Missouri, since August 2004and as an associated staff member of the Department of Anesthesia at the DePaul Health Center in Bridgeton, Missouri, since 1995.
"We enthusiastically welcome Chuck and Barry to our Board of Directors and look forward to benefiting from their significant knowledge and experience as we continue to grow and expand our business," said Dr. Frank E. O'Donnell, Jr., BDSI's Executive Chairman.
Dr. Mark A. Sirgo, BDSI's President and Chief Executive Officer added, "Chuck and Barry join our BDSI Board at a very exciting time for the Company as we prepare to launch our first product, BUNAVAIL, for the maintenance treatment of opioid dependence. Chuck brings with him over thirty years of commercial launch and operations experience from such companies as GlaxoSmithKline and Covidien and has sales and marketing expertise with major brands such as Advair and pain products at Covidien such as Exalgo®. Dr. Feinberg is a Pain Management specialist who has been treating patients for over twenty years. As BDSI plans to continue to place an emphasis on pain therapeutics, his expertise will be of significant value both from the clinical and the business perspective. We welcome both Chuck and Barry to our Board."
About BioDelivery Sciences International
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.
BDSI's development strategy focuses on utilization of the FDA's 505(b)(2) approval process. This regulatory pathway creates the potential for more timely and efficient approval of new formulations of previously approved therapeutics.
BDSI's particular area of focus is the development and commercialization of products in the areas of pain management and addiction. These are areas where BDSI believes its drug delivery technologies and products can best be applied to address critical unmet medical needs. BDSI's marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence.
BDSI's headquarters is located in Raleigh, North Carolina.
For more information visit www.bdsi.com.